Pet Cancer Therapeutics Market to hit USD 760 million by 2030, says Global Market Insights Inc.
August 16, 2022 03:15 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The pet cancer therapeutics market value is anticipated to be valued over USD 760 million by 2030. Rising awareness pertaining to pet diseases...
Global Oncology Drugs Market Report 2022-2027: Featuring Key Players F. Hoffmann-La Roche, Novartis, Bristol-Myers Squibb, Merck & Co, Johnson & Johnson, Pfizer & Others
August 12, 2022 07:48 ET
|
Research and Markets
Dublin, Aug. 12, 2022 (GLOBE NEWSWIRE) -- The "Global Oncology Drugs Market (2022-2027) by Drug Class, Indication, End-user, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff...
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
August 11, 2022 16:02 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
August 09, 2022 16:30 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
Immatics veröffentlicht Ergebnisse des zweiten Quartals 2022 sowie ein Update zur Geschäftsentwicklung
August 09, 2022 07:00 ET
|
Immatics N.V.
Patientenrekrutierung in allen drei Phase-1b-Studienkohorten mit ACTengine® IMA203 TCR-T-Zelltherapiekandidaten (Zielstruktur: PRAME) gestartet: IMA203 Monotherapie mit vorläufiger, empfohlener...
Immatics Announces Second Quarter 2022 Financial Results and Business Update
August 09, 2022 07:00 ET
|
https://immatics.com/
ACTengine® TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: IMA203 monotherapy at provisional recommended Phase 2 dose (RP2D) (Cohort A), IMA203/nivolumab...
Natural Killer (NK) Cell Therapeutics Market Research Report 2022
August 09, 2022 06:08 ET
|
Research and Markets
Dublin, Aug. 09, 2022 (GLOBE NEWSWIRE) -- The "Natural Killer (NK) Cell Therapeutics Market - A Global and Regional Analysis: Focus on NK Cell Therapy Type, Indication, Country, Pipeline Analysis,...
Global Cancer Immunotherapy Market to Reach $90.53 Billion by 2027
August 09, 2022 05:13 ET
|
Research and Markets
Dublin, Aug. 09, 2022 (GLOBE NEWSWIRE) -- The "Global Cancer Immunotherapy Market (2022-2027) by Product, Application, End User, Geography, Competitive Analysis and the Impact of Covid-19 with...
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
August 04, 2022 16:05 ET
|
Lyell Immunopharma, Inc
Cash, cash equivalents and marketable securities of $787.0 million as of June 30, 2022 provides funding into 2025 and supports advancement of multiple product candidates through key clinical...
Asia Pacific Cancer Gene Therapy Market Report 2022: Featuring Key Players Novartis, GlaxoSmithKline, Amgen, Bristol Myers Squibb, Gilead Sciences,. Adaptimmune, Genelux & Sarepta Therapeutics,
August 04, 2022 04:53 ET
|
Research and Markets
Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "Asia Pacific Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic...